Last reviewed · How we verify
Peginterferon alfa-2b Injection
Peginterferon alfa-2b is a pegylated form of interferon alfa-2b that binds to interferon-alpha receptors on immune cells to enhance antiviral and anti-tumor immune responses.
Peginterferon alfa-2b is a pegylated form of interferon alfa-2b that binds to interferon-alpha receptors on immune cells to enhance antiviral and anti-tumor immune responses. Used for Chronic hepatitis B, Chronic hepatitis C, Melanoma.
At a glance
| Generic name | Peginterferon alfa-2b Injection |
|---|---|
| Sponsor | Nanfang Hospital, Southern Medical University |
| Drug class | Interferon alfa |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Peginterferon alfa-2b is a recombinant interferon alfa-2b conjugated with polyethylene glycol (PEG), which extends its half-life and duration of action. It activates natural killer cells, macrophages, and cytotoxic T lymphocytes, enhancing the body's immune response against viral infections and malignant cells. The pegylation allows for less frequent dosing compared to non-pegylated interferon alfa-2b.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
- Melanoma
- Follicular lymphoma
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Depression
- Thrombocytopenia
- Neutropenia
- Injection site reactions
Key clinical trials
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET (PHASE2)
- Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B (PHASE4)
- Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases (PHASE1)
- A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis (NA)
- Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg (PHASE4)
- Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia (NA)
- A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: